{"schema_version":"secwatch.filing_event.v1","accession":"0001649094-25-000057","form_type":"8-K","ticker":"PCVX","cik":"0001649094","company_name":"Vaxcyte, Inc.","filed_at":"2025-05-01T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.190776+00:00","generated_at":"2026-05-23T00:38:10.838221+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"Vaxcyte appoints Dr. Olivier Brandicourt to board of directors","bullets":["Appointment effective May 1, 2025 as a Class III director with term expiring at 2026 annual meeting.","Board determined Dr. Brandicourt qualifies as independent under Nasdaq rules.","Receives initial equity award of $800,000 in nonstatutory stock options vesting over 36 months.","Annual cash retainer of $50,000 and annual equity award of $450,000 (75% option, 25% RSU).","Standard indemnification agreement entered; no reportable transactions per Item 404(a)."],"urls":{"canonical":"https://secwatch.observer/filing/0001649094-25-000057","json":"https://secwatch.observer/filing/0001649094-25-000057.json","markdown":"https://secwatch.observer/filing/0001649094-25-000057.md","text":"https://secwatch.observer/filing/0001649094-25-000057.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1649094/000164909425000057/0001649094-25-000057-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1649094/000164909425000057/pcvx-20250501.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-23T00:38:10.838221+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a2e27b2c26","claim":"Dr. Olivier Brandicourt was appointed as Director at Vaxcyte, Inc..","evidence_excerpt":"On May 1, 2025, upon recommendation of the Nominating and Corporate Governance Committee, the Board of Directors (the “Board”) of Vaxcyte, Inc. (the “Company”) appointed Dr. Olivier Brandicourt to the Board as a Class III director, which appointment became effective immediately.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1649094/000164909425000057/0001649094-25-000057-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}